Kalaris Therapeutics (KLRS) Misses Q3 EPS by 64c
Tweet
Share
E-mailGet Alerts KLRS Hot Sheet
Join SI Premium – FREE
Kalaris Therapeutics (NASDAQ: KLRS) reported Q3 EPS of ($0.64).
For earnings history and earnings-related data on Kalaris Therapeutics (KLRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA maintains underperform ratings on six BDC stocks
- Is the global equity rally broadening? UBS weighs in
- Alzamend Neuro (ALZN) files for 98.4M share offering by selling stockholders
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
